New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
06:56 EDTLLYEli Lilly provides update on next steps for Solanezumab
Eli Lilly provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease. Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional Phase 3 study of solanezumab in patients with mild Alzheimer's disease. Additional details, including study design and length, are still being determined. Lilly expects to initiate this study no later than 3Q2013. Based on recent meetings with the FDA, Lilly does not intend to submit a Biologics License Application at this time in the U.S. based solely on the existing analyses of data from the Expedition studies. Lilly will continue to analyze and discuss the data from the two, Phase 3, double-blind, placebo-controlled solanezumab Expedition studies with regulators globally to determine the regulatory paths forward in different regions. It is possible that different courses of action could be taken in different jurisdictions.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:48 EDTLLYBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
08:53 EDTLLYBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
05:39 EDTLLYEli Lilly, Adocia to co-develop BioChaperone Lispro
Subscribe for More Information
December 16, 2014
14:48 EDTLLYEli Lilly's CYRAMZA receives third FDA approval
Subscribe for More Information
December 15, 2014
16:33 EDTLLYEli Lilly raises quarterly dividend 2% to 50c per share
Subscribe for More Information
December 12, 2014
12:52 EDTLLYEli Lilly: FDA expands approved use of Cyramza to treat lung cancer
Subscribe for More Information
December 11, 2014
10:13 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTLLYEli Lilly upgraded at Morgan Stanley
As previously reported, Morgan Stanley upgraded Eli Lilly two notches to Overweight from Underweight. The firm has increased confidence in Eli Lilly's pipeline investments following recent external data in Alzheimer's and atherosclerosis and now expects potential evacetrapib peak sales of $3B and solanezumab peak sales of $10B. Price target raised to $85 from $60.
06:22 EDTLLYEli Lilly upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
December 9, 2014
07:44 EDTLLYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use